## Grigorios Giamouzis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9996502/publications.pdf

Version: 2024-02-01

90 papers

2,877 citations

236925 25 h-index 52 g-index

95 all docs 95 docs citations

95 times ranked

4457 citing authors

#	Article	IF	CITATIONS
1	The Sympathetic Nervous System in Heart Failure. Journal of the American College of Cardiology, 2009, 54, 1747-1762.	2.8	789
2	Hospitalization Epidemic in Patients With Heart Failure: Risk Factors, Risk Prediction, Knowledge Gaps, and Future Directions. Journal of Cardiac Failure, 2011, 17, 54-75.	1.7	240
3	Reframing the association and significance of coâ€morbidities in heart failure. European Journal of Heart Failure, 2016, 18, 744-758.	7.1	169
4	Impact of Dopamine Infusion on Renal Function in Hospitalized Heart Failure Patients: Results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. Journal of Cardiac Failure, 2010, 16, 922-930.	1.7	153
5	Utility of the Seattle Heart Failure Model in Patients With Advanced Heart Failure. Journal of the American College of Cardiology, 2009, 53, 334-342.	2.8	144
6	Global left atrial failure in heart failure. European Journal of Heart Failure, 2016, 18, 1307-1320.	7.1	104
7	Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. International Journal of Cardiology, 2014, 172, 115-121.	1.7	96
8	Patientâ€Reported Selective Adherence to Heart Failure Selfâ€Care Recommendations: A Prospective Cohort Study: The Atlanta Cardiomyopathy Consortium. Congestive Heart Failure, 2013, 19, 16-24.	2.0	77
9	The medical and socioeconomic burden of heart failure: A comparative delineation with cancer. International Journal of Cardiology, 2016, 203, 279-281.	1.7	64
10	A 6-Month Follow-up of Intermittent Levosimendan Administration Effect on Systolic Function, Specific Activity Questionnaire, and Arrhythmia in Advanced Heart Failure. Journal of Cardiac Failure, 2007, 13, 556-559.	1.7	60
11	Digoxin Therapy Does Not Improve Outcomes in Patients With Advanced Heart Failure on Contemporary Medical Therapy. Circulation: Heart Failure, 2009, 2, 90-97.	3.9	48
12	A Propensity-Matched Study of the Association of Cardiothoracic Ratio With Morbidity and Mortality in Chronic Heart Failure. American Journal of Cardiology, 2008, 101, 343-347.	1.6	46
13	Incremental value of renal function in risk prediction with the Seattle Heart Failure Model. American Heart Journal, 2009, 157, 299-305.	2.7	46
14	Inflammatory cytokine gene variants in coronary artery disease patients in Greece. Coronary Artery Disease, 2008, 19, 575-582.	0.7	45
15	Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure. Health Policy, 2017, 121, 363-377.	3.0	43
16	Diabetic cardiovascular autonomic neuropathy: clinical implications. Expert Review of Cardiovascular Therapy, 2012, 10, 747-765.	1.5	41
17	Increased Number of Circulating Progenitor Cells After Implantation of Ventricular Assist Devices. Journal of Heart and Lung Transplantation, 2009, 28, 710-717.	0.6	35
18	Echocardiography and Risk Prediction in Advanced Heart Failure: Incremental Value Over Clinical Markers. Journal of Cardiac Failure, 2009, 15, 586-592.	1.7	33

#	Article	IF	CITATIONS
19	Effect of a special carbohydrate–protein bar and tomato juice supplementation on oxidative stress markers and vascular endothelial dynamics in ultra-marathon runners. Food and Chemical Toxicology, 2014, 69, 231-236.	3.6	33
20	Left ventricular geometry as a major determinant of left ventricular ejection fraction: physiological considerations and clinical implications. European Journal of Heart Failure, 2018, 20, 436-444.	7.1	31
21	Red Blood Cell Distribution Width in Heart Failure: Pathophysiology, Prognostic Role, Controversies and Dilemmas. Journal of Clinical Medicine, 2022, 11, 1951.	2.4	31
22	Renal Function in Advanced Heart Failure. Congestive Heart Failure, 2011, 17, 180-188.	2.0	27
23	The Emerging Role of Galectin-3 and ST2 in Heart Failure: Practical Considerations and Pitfalls Using Novel Biomarkers. Current Heart Failure Reports, 2013, 10, 441-449.	3.3	27
24	Patient Perception Versus Medical Record Entry of Health-Related Conditions Among Patients With Heart Failure. American Journal of Cardiology, 2011, 107, 569-572.	1.6	26
25	Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. International Journal of Cardiology, 2017, 243, 389-395.	1.7	26
26	The heart failure pandemic: The clinical and economic burden in Greece. International Journal of Cardiology, 2017, 227, 923-929.	1.7	26
27	The cardiorenal syndrome in heart failure: cardiac? renal? syndrome?. Heart Failure Reviews, 2012, 17, 355-366.	3.9	25
28	lloprost for prevention of contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure. Results of a randomized pilot study. European Journal of Clinical Pharmacology, 2006, 62, 589-595.	1.9	24
29	Association Between Epicardial Fat Thickness and Weight Homeostasis Hormones in Patients With Noncachectic Heart Failure. Angiology, 2013, 64, 173-180.	1.8	21
30	Epidemiology and Importance of Renal Dysfunction in Heart Failure Patients. Current Heart Failure Reports, 2013, 10, 411-420.	3.3	20
31	SPECT and PET in ischemic heart failure. Heart Failure Reviews, 2017, 22, 243-261.	3.9	20
32	A simple score for early risk stratification in acute heart failure. International Journal of Cardiology, 2017, 230, 248-254.	1.7	19
33	Left atrial volume index in patients with heart failure and severely impaired left ventricular systolic function: the role of established echocardiographic parameters, circulating cystatin C and galectin-3. Therapeutic Advances in Cardiovascular Disease, 2017, 11, 283-295.	2.1	19
34	Left ventricular hypertrophy and sudden cardiac death. Heart Failure Reviews, 2022, 27, 711-724.	3.9	19
35	Acute hemodynamic effects of moderate doses of nebivolol versus metoprolol in patients with systolic heart failure. International Journal of Clinical Pharmacology and Therapeutics, 2007, 45, 71-77.	0.6	19
36	Metformin Use in Patients With Diabetes Mellitus and Heart Failure: Friend or Foe?. Journal of Cardiac Failure, 2010, 16, 207-210.	1.7	15

#	Article	IF	CITATIONS
37	Ranolazine Added to Amiodarone Facilitates Earlier Conversion of Atrial Fibrillation Compared to Amiodaroneâ€Only Therapy. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 372-378.	1.2	15
38	The management of atrial fibrillation in heart failure: an expert panel consensus. Heart Failure Reviews, 2020, 26, 1345-1358.	3.9	15
39	ACE2, the Counter-Regulatory Renin–Angiotensin System Axis and COVID-19 Severity. Journal of Clinical Medicine, 2021, 10, 3885.	2.4	14
40	Epidemiology of stroke in chronic heart failure patients with normal sinus rhythm: Findings from the DIG stroke sub-study. International Journal of Cardiology, 2010, 144, 389-393.	1.7	13
41	Incident coronary revascularization and subsequent mortality in chronic heart failure: A propensity-matched study. International Journal of Cardiology, 2010, 140, 55-59.	1.7	12
42	Relationship Between Heart Failure and Lipids: The Paradigm Continues to Evolve. Journal of Cardiac Failure, 2007, 13, 254-258.	1.7	11
43	Natriuretic peptide-guided levosimendan therapy for heart failure: A promising new approach. International Journal of Cardiology, 2008, 128, 91-93.	1.7	11
44	Race and the Natural History of Chronic Heart Failure: A Propensity-Matched Study. Journal of Cardiac Failure, 2008, 14, 373-378.	1.7	10
45	Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes?. Lancet Diabetes and Endocrinology,the, 2017, 5, 314-315.	11.4	9
46	Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper. Heart Failure Reviews, 2021, , 1.	3.9	9
47	Renal biomarkers and outcomes in outpatients with heart failure: The Atlanta cardiomyopathy consortium. International Journal of Cardiology, 2016, 218, 136-143.	1.7	8
48	Management of iron deficiency in chronic heart failure: Practical considerations for clinical use and future directions. European Journal of Internal Medicine, 2019, 65, 17-25.	2.2	8
49	Polymorphisms of Renin-Angiotensin System and Natriuretic Peptide Receptor A Genes in Patients of Greek Origin with a History of Myocardial Infarction. Angiology, 2010, 61, 737-743.	1.8	7
50	NGAL and ST2 levels in ambulatory patients with chronic heart failure. Clinical and echocardiographic correlates. Scandinavian Cardiovascular Journal, 2015, 49, 213-219.	1.2	7
51	Impact of renin–angiotensin–aldosterone system polymorphisms on myocardial perfusion: Correlations with myocardial single photon emission computed tomography-derived parameters. Journal of Nuclear Cardiology, 2019, 26, 1298-1308.	2.1	7
52	Relative contribution of risk factors/coâ€morbidities to heart failure pathogenesis: interaction with ejection fraction. ESC Heart Failure, 2020, 7, 4399-4403.	3.1	6
53	Relationship between tumor necrosis factor- $\hat{l}_{\pm}$ (TNFA) gene polymorphisms and cardiac sarcoidosis. In Vivo, 2014, 28, 1125-9.	1.3	6
54	The Interventricular Septum: Structure, Function, Dysfunction, and Diseases. Journal of Clinical Medicine, 2022, 11, 3227.	2.4	6

#	Article	IF	Citations
55	The importance of managing diabetes correctly to prevent heart failure. Expert Review of Cardiovascular Therapy, 2011, 9, 257-259.	1.5	5
56	Red blood cell distribution width in elderly hospitalized patients with cardiovascular disease. World Journal of Cardiology, 2021, 13, 503-513.	1.5	5
57	Acute aortic dissection is independent of weather conditions but statistically correlates with day of the week. Journal of Emergencies, Trauma and Shock, 2014, 7, 244.	0.7	4
58	Practical Recommendations for the Diagnosis and Medical Management of Stable Angina. Journal of Cardiovascular Pharmacology, 2019, 74, 308-314.	1.9	4
59	A Struggle to SURVIVE: To Abandon or not to Abandon Levosimendan?. Cardiovascular Drugs and Therapy, 2007, 21, 401-402.	2.6	3
60	A case of balloon pulmonary angioplasty as a palliative therapy in chronic thromboembolic pulmonary hypertension. Hellenic Journal of Cardiology, 2016, 57, 363-365.	1.0	3
61	Cystatin C and galectin-3 as therapeutic targets in heart failure. Therapeutic Advances in Cardiovascular Disease, 2018, 12, 233-235.	2.1	3
62	Hospitalization affects the anticoagulation patterns of patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2019, 48, 225-232.	2.1	3
63	Chronic Obstructive Pulmonary Disease as a Main Factor of Premature Aging. International Journal of Environmental Research and Public Health, 2019, 16, 540.	2.6	3
64	Coexisting morbidity burden in elderly hospitalized patients with and without heart failure. Hellenic Journal of Cardiology, 2022, , .	1.0	3
65	Coexisting Morbidities in Heart Failure: No Robust Interaction with the Left Ventricular Ejection Fraction. Current Heart Failure Reports, 2020, 17, 133-144.	3.3	2
66	Diagnosis of coronary artery disease: potential complications of imaging techniques. Acta Cardiologica, 2021, , 1-4.	0.9	2
67	Coexisting Morbidity Burden in Hospitalized Elderly Patients with New-Onset Heart Failure vs Acutely Decompensated Chronic Heart Failure. Angiology, 2022, , 000331972110626.	1.8	1
68	Validation of the Seattle Heart Failure Model in Patients Referred for Transplant Evaluation. Journal of Cardiac Failure, 2007, 13, S159-S160.	1.7	0
69	Lack of Racial Variations in the Natural History of Chronic Heart Failure: A Propensity-Matched Study. Journal of Cardiac Failure, 2007, 13, S163.	1.7	0
70	Increased Cardiothoracic Ratio and Adverse Outcomes in Chronic Heart Failure: A Propensity-Matched Study. Journal of Cardiac Failure, 2007, 13, S167.	1.7	0
71	The Predictive Value of Left Atrial Volume in Patients Referred for Transplant Evaluation. Journal of Cardiac Failure, 2007, 13, S168-S169.	1.7	0
72	The Influence of Cardiopulmonary Exercise Testing and Renal Function on the Predictive Capability of the Seattle Heart Failure Model. Journal of Cardiac Failure, 2007, 13, S158.	1.7	0

#	Article	IF	CITATIONS
73	184: Utility of the Seattle Heart Failure Model in Patients with Advanced Heart Failure Treated with Implantable Cardioverter Defibrillators and/or Biventricular Pacemakers. Journal of Heart and Lung Transplantation, 2008, 27, S126-S127.	0.6	O
74	338: Utility of the Seattle Heart Failure Model in Medically Treated Patients with Advanced Heart Failure. Journal of Heart and Lung Transplantation, 2008, 27, S182-S183.	0.6	0
75	Racial Variations in Outcomes with Diuretics in Advanced Heart Failure. Journal of Cardiac Failure, 2008, 14, S89.	1.7	0
76	Incident Coronary Revascularization and Subsequent Mortality in Systolic and Diastolic Heart Failure: A Propensity-Matched Study. Journal of Cardiac Failure, 2008, 14, S92.	1.7	0
77	Digoxin Is an Independent Predictor of Outcomes in Contemporary Advanced Heart Failure Patients in Addition to the Seattle Heart Failure Model. Journal of Cardiac Failure, 2008, 14, S96.	1.7	0
78	Digoxin and Outcomes in Patients with Advanced Heart Failure and Contemporary Optimal Treatment. Journal of Cardiac Failure, 2008, 14, S97.	1.7	0
79	The Role of Renal Function Markers on the Discriminative Properties of the Seattle Heart Failure Model in Patients with Advanced Heart Failure. Journal of Cardiac Failure, 2008, 14, S82.	1.7	0
80	Racial Variations in the Incidence and Outcomes of Stroke in Chronic Heart Failure Patients with Normal Sinus Rhythm. Journal of Cardiac Failure, 2008, 14, S84.	1.7	0
81	Predicting Risk among Patients Listed for Heart Transplantation: Is It the Same as a General Heart Failure Population?. Journal of Cardiac Failure, 2009, 15, S102.	1.7	0
82	High-Output Cardiomyopathy Regression Following Percutaneous Closure of Left Internal Mammary and Subclavian to Pulmonary Artery Fistulae. Circulation Journal, 2010, 74, 1260-1261.	1.6	0
83	Increased Levels of Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Are Independently Associated with Adverse Outcomes in Outpatients with Heart Failure. Journal of Cardiac Failure, 2010, 16, S32-S33.	1.7	0
84	Patients' Reporting Versus Electronic Health Record Documentation of Comorbidities among Heart Failure Patients. Journal of Cardiac Failure, 2010, 16, S104.	1.7	0
85	Health Literacy, Self-Reported Education and Outcomes among Heart Failure Outpatients. Journal of Cardiac Failure, 2010, 16, S108.	1.7	0
86	Distribution, Treatment, and Health Record Documentation of Depression Symptoms in Heart Failure Outpatients. Journal of Cardiac Failure, 2010, 16, S111.	1.7	0
87	Favorable Pulse Wave Augmentation Indices and Left Ventricular Diastolic Profile in β-Thalassemia Minor. Angiology, 2017, 68, 899-906.	1.8	0
88	Abstract 2307: Seattle Heart Failure Model Overestimates Time to Mortality in Patients Referred for Heart Transplantation. Circulation, 2007, $116$ , .	1.6	0
89	Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes. World Journal of Cardiology, 2022, 14, 266-270.	1.5	0
90	Digoxin, Diuretics, and Vasodilators in Patients with Heart Failure., 0,, 77-94.		0